{"id":178550,"date":"2026-01-30T08:50:31","date_gmt":"2026-01-30T13:50:31","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=178550"},"modified":"2026-01-30T08:50:31","modified_gmt":"2026-01-30T13:50:31","slug":"hester-biosciences-reports-140-increase-in-q3-net-profit-amid-poultry-and-petcare-segment-growth","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/hester-biosciences-reports-140-increase-in-q3-net-profit-amid-poultry-and-petcare-segment-growth\/","title":{"rendered":"Hester Biosciences Reports 140% Increase in Q3 Net Profit Amid Poultry and Petcare Segment Growth"},"content":{"rendered":"\n

Hester Biosciences Limited<\/strong> (HESTERBIO:NSE), India’s second-largest poultry vaccine manufacturer, announced exceptional third-quarter results today with consolidated net profit climbing 140% year-over-year to \u20b9106.69 crore. The stock closed at \u20b91,483 as of January 30, 2026, valuing the company at \u20b91,222 crore market capitalization.<\/p>\n\n\n\n

Quarterly Results<\/strong><\/h2>\n\n\n\n

Hester Biosciences announced a consolidated net profit of \u20b9106.69 crore for the quarter ended December 2025, representing a 140% increase year-over-year. Standalone revenue for the period reached \u20b984 crore, while consolidated revenue rose 12% to approximately \u20b990.40 crore. The Poultry Healthcare Division recorded a 32% increase in sales, while vaccine sales specifically grew by 20%. The Petcare Division achieved growth of 105% during the quarter. These results indicate a profit turnaround driven by operational efficiency and margin expansion despite relatively modest topline growth. This indicates a significant profit turnaround.<\/p>\n\n\n\n

Annual Performance Context<\/strong><\/h2>\n\n\n\n

For the nine-month period ending December 2025, Poultry Healthcare revenues increased 20% and vaccine sales expanded 27%. The Petcare Division grew 38% over the same period. During the full fiscal year 2025, the company generated \u20b9286.32 crore in revenue and a net profit of \u20b931.84 crore, reflecting 17.24% annual profitability growth. Earnings per share for FY25 were \u20b937.43, and an equity dividend of \u20b97 per share was maintained. Growth exceeded historical single-quarter profit levels. Cumulative nine-month performance reinforced underlying business momentum through manufacturing efficiency gains.<\/p>\n\n\n\n

Business and Operations Update<\/strong><\/h2>\n\n\n\n

Animal Healthcare performance normalized in Q3 following delays in government immunization programs during the first half of the fiscal year. Hester maintains a 75% domestic market share in PPR vaccines. International operations in the African markets transitioned to a profit of \u20b95 crore on revenue of \u20b917 crore, a turnaround from previous losses. Profitability was impacted by material currency gains from exchange rate fluctuations, including \u20b97.83 crore in unrealized foreign exchange gains. In the poultry sector, management noted the stabilization of feed costs and bird placement cycles that historically pressured industry margins. Management focused on internal cost structures.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Forward Outlook<\/strong><\/h2>\n\n\n\n

Management plans to launch an Avian Influenza vaccine during FY26, targeting both retail availability and export opportunities. This rollout represents the first major product launch in this segment in recent years. The company is prioritizing the execution of government tenders for PPR and Lumpy Skin Disease. While no formal forward earnings guidance was provided for the remainder of FY26, management expects normalized institutional demand and contributions from new product entries. Continued tracking of gross margins and operating expense ratios is required to assess the sustainability of recent efficiency gains.<\/p>\n\n\n\n

Performance Summary<\/strong><\/h2>\n\n\n\n

Hester Biosciences\u2019 market capitalization stood at \u20b91,225 crore with a closing stock price of \u20b91,440. This price reflects a 39% decline from the 52-week high of \u20b92,350. The surge in profitability is attributed to cost control measures and manufacturing leverage rather than volume acceleration. The company\u2019s diversification into companion animal products and the turnaround in African markets provide additional growth channels. Investors continue to monitor the execution timelines of government programs and the impact of currency fluctuations. The company maintains strategic presence in thirty countries.<\/p>\n","protected":false},"excerpt":{"rendered":"

Hester Biosciences Limited (HESTERBIO:NSE), India’s second-largest poultry vaccine manufacturer, announced exceptional third-quarter results today with consolidated net profit climbing 140% year-over-year to \u20b9106.69 crore. The stock closed at \u20b91,483 as of January 30, 2026, valuing the company at \u20b91,222 crore market capitalization. Quarterly Results Hester Biosciences announced a consolidated net profit of \u20b9106.69 crore for […]<\/p>\n","protected":false},"author":2396,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5,1941,5747],"tags":[15195,10169,15193,15194],"class_list":["post-178550","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest","category-stock-analysis","category-healthcare-stocks","tag-animal-healthcare","tag-earnings","tag-hester-biosciences","tag-hesterbio"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":175862,"url":"https:\/\/alphastreet.com\/india\/hester-biosciences-limited-hesterbio-q2-2025-earnings-call-transcript\/","url_meta":{"origin":178550,"position":0},"title":"Hester Biosciences Limited (HESTERBIO) Q2 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Hester Biosciences Limited (NSE: HESTERBIO) Q2 2025 Earnings Call dated Oct. 28, 2024 Corporate Participants: Unidentified Speaker Priya Gandhi \u2014 Executive Director Rajiv Gandhi \u2014 Chief Executive Officer and Managing Director Analysts: Nisha \u2014 Analyst Presentation: Operator Ladies and gentlemen, good day and welcome to the Hester BioScience Q2 H1\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":151735,"url":"https:\/\/alphastreet.com\/india\/hester-biosciences-ltd-q1fy24-88-rise-in-profits\/","url_meta":{"origin":178550,"position":1},"title":"Hester Biosciences Ltd Q1FY24; 88% rise in Profits","author":"Hardik Bhandare","date":"August 8, 2023","format":false,"excerpt":"Hester Biosciences Ltd is one of the leading animal health care companies & the second largest poultry vaccine manufacturer in India. Founded by Mr. Rajiv Gandhi in 1987, it has now a presence in over 30 countries & has a key market in India, Nepal & Tanzania Partners with Bill\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-356.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-356.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-356.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-356.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-356.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-356.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":175859,"url":"https:\/\/alphastreet.com\/india\/hester-biosciences-limited-hesterbio-q1-2026-earnings-call-transcript\/","url_meta":{"origin":178550,"position":2},"title":"Hester Biosciences Limited (HESTERBIO) Q1 2026 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Hester Biosciences Limited (NSE: HESTERBIO) Q1 2026 Earnings Call dated Aug. 01, 2025 Corporate Participants: Unidentified Speaker Nisha Shetty Rajiv Gandhi \u2014 Chief Executive Officer and Managing Director Nikhil Jhanwar \u2014 Chief Financial Officer Priya Gandhi \u2014 Deputy Director - Business Operations Analysts: Unidentified Participant Rushab Shah \u2014 Analyst Meg\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":139666,"url":"https:\/\/alphastreet.com\/india\/hester-biosciences-limited-hesterbio-q3-fy23-earnings-concall-transcript\/","url_meta":{"origin":178550,"position":3},"title":"Hester Biosciences Limited (HESTERBIO) Q3 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"January 31, 2023","format":false,"excerpt":"Hester Biosciences Limited (NSE:HESTERBIO) Q3 FY23 Earnings Concall dated Jan. 31, 2023. Corporate Participants: Rajiv Gandhi\u00a0--\u00a0Chief Executive Officer and Managing Director Priya Gandhi\u00a0--\u00a0Executive Director Nikhil Jhanwar\u00a0--\u00a0Chief Financial Officer Analysts: Rohan John\u00a0--\u00a0ICICI Securities Limited -- Analyst Manish Gupta\u00a0--\u00a0Solidarity Investment Managers -- Analyst Manish Jain\u00a0--\u00a0GormalOne LLP -- Analyst Keshav Garg\u00a0--\u00a0Counter Cyclical Investments\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":178960,"url":"https:\/\/alphastreet.com\/india\/hester-biosciences-limited-hesterbio-q3-2026-earnings-call-transcript\/","url_meta":{"origin":178550,"position":4},"title":"Hester Biosciences Limited (HESTERBIO) Q3 2026 Earnings Call Transcript","author":"News desk","date":"February 2, 2026","format":false,"excerpt":"Hester Biosciences Limited (NSE: HESTERBIO) Q3 2026 Earnings Call dated Jan. 30, 2026 Corporate Participants: Unidentified Speaker Nisha Shetty Rajiv Gandhi \u2014 Chief Executive Officer & Managing Director Priya Gandhi \u2014 Executive Director Analysts: Madhur Rathi \u2014 Analyst Hershel Mehta \u2014 Analyst ravi Mehta \u2014 Analyst Arya Shah \u2014 Analyst\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":175861,"url":"https:\/\/alphastreet.com\/india\/hester-biosciences-limited-hesterbio-q3-2025-earnings-call-transcript\/","url_meta":{"origin":178550,"position":5},"title":"Hester Biosciences Limited (HESTERBIO) Q3 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Hester Biosciences Limited (NSE: HESTERBIO) Q3 2025 Earnings Call dated Jan. 30, 2025 Corporate Participants: Rajiv Gandhi \u2014 Executive CEO, MD & Executive Director Priya Gandhi \u2014 Executive Director Analysts: Nisha Shetty \u2014 Analyst Rushabh Shah \u2014 Analyst Unidentified Participant Himanshu Upadhyay \u2014 Analyst Keshav Garg \u2014 Analyst Utsav Adani\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2396"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=178550"}],"version-history":[{"count":3,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178550\/revisions"}],"predecessor-version":[{"id":178559,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178550\/revisions\/178559"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=178550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=178550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=178550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}